NCT04552704: CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must be receiving immune checkpoint inhibitor therapy & have grade 2 or 3 immune related adverse events (e.g. diarrhea/colitis, pneumonitis, elevated creatine in kidneys, elevated liver enzymes, skin rash)

Comments are closed.

Up ↑